DARE (Dare Bioscience) Current Accrued Expense: $0.45 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DARE Dare Bioscience Inc DARE
19 GF Score
Price $0.71
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience Current Accrued Expense?

Dare Bioscience DARE -2.23% 19 Current Accrued Expense is $0.45 Mil as of Jun. 2026. GuruFocus rates DARE with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Dare Bioscience's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.45 Mil.

Dare Bioscience's quarterly Current Accrued Expense declined from Dec. 2025 ($0.53 Mil) to Mar. 2026 ($0.53 Mil) and declined from Mar. 2026 ($0.53 Mil) to Jun. 2026 ($0.45 Mil).

Dare Bioscience's annual Current Accrued Expense increased from Dec. 2023 ($1.81 Mil) to Dec. 2024 ($1.99 Mil) but then declined from Dec. 2024 ($1.99 Mil) to Dec. 2025 ($0.53 Mil).

Dare Bioscience Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Dare Bioscience's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience Current Accrued Expense Chart

Dare Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 9.17 1.81 1.99 0.53

Dare Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.52 2.33 0.53 0.53 0.45
DARE
19GF Score
Dare Bioscience Inc DARE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dare Bioscience Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.45 Mil mean?
Dare Bioscience (DARE) has a Current Accrued Expense of $0.45 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Dare Bioscience and its competitors.
Is Dare Bioscience's Current Accrued Expense too high?
Dare Bioscience's current Current Accrued Expense is $0.45 Mil. Overall, Dare Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Current Accrued Expense compare to OTLC and PASG?
Dare Bioscience's Current Accrued Expense of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current Current Accrued Expense is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Current Accrued Expense of $0.45 Mil. The current Current Accrued Expense is $0.45 Mil. Dare Bioscience's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Current Accrued Expense is $0.45 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
19GF Score

Get the complete analysis for DARE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price